Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. (SHA:603168)
China · Delayed Price · Currency is CNY 6.74
0.00 (0.00%)
Apr 30, 2026, 3:00 PM CST
SHA:603168 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 439.37 | 472.1 | 638.03 | 539.77 | 627.6 |
Other Revenue | 23.41 | 11.86 | 6.94 | 9.77 | 2.16 |
| 462.78 | 483.96 | 644.97 | 549.54 | 629.76 | |
Revenue Growth (YoY) | -4.38% | -24.96% | 17.37% | -12.74% | 81.59% |
Cost of Revenue | 267.67 | 252.67 | 288.12 | 233.57 | 232.59 |
Gross Profit | 195.11 | 231.29 | 356.85 | 315.97 | 397.18 |
Selling, General & Admin | 191.11 | 225.31 | 268.63 | 206.47 | 243.41 |
Research & Development | 25.2 | 57.58 | 64.45 | 59.61 | 102.21 |
Other Operating Expenses | 5.79 | 4.96 | 6.16 | 5.94 | 8.24 |
Operating Expenses | 227.08 | 289.02 | 336.15 | 276.34 | 355.58 |
Operating Income | -31.96 | -57.73 | 20.71 | 39.62 | 41.6 |
Interest Expense | -8.97 | -8.3 | -4.61 | -1.64 | -0.77 |
Interest & Investment Income | 28.86 | 1.92 | 17.41 | 3.08 | 9.63 |
Other Non Operating Income (Expenses) | -0.26 | -0.23 | -0.27 | -0.18 | -0.11 |
EBT Excluding Unusual Items | -12.33 | -64.35 | 33.23 | 40.87 | 50.35 |
Impairment of Goodwill | -198.55 | -33.34 | -13.3 | -9.48 | - |
Gain (Loss) on Sale of Investments | 0.12 | -16.92 | 1.19 | 6.97 | 2.64 |
Gain (Loss) on Sale of Assets | 0.9 | 1.05 | -0.01 | 15.82 | -0.21 |
Asset Writedown | -35.45 | - | - | - | - |
Legal Settlements | -0.7 | -1.4 | -2.76 | - | - |
Other Unusual Items | 6.07 | -0.61 | 14.73 | -0.17 | -3.9 |
Pretax Income | -239.93 | -115.57 | 33.08 | 54.01 | 48.87 |
Income Tax Expense | -1.21 | 5.92 | 7.97 | 9.26 | 13.22 |
Earnings From Continuing Operations | -238.73 | -121.49 | 25.1 | 44.75 | 35.66 |
Net Income to Company | -238.73 | -121.49 | 25.1 | 44.75 | 35.66 |
Minority Interest in Earnings | 0 | -1.95 | 0.3 | -0 | - |
Net Income | -238.72 | -123.44 | 25.41 | 44.75 | 35.66 |
Net Income to Common | -238.72 | -123.44 | 25.41 | 44.75 | 35.66 |
Net Income Growth | - | - | -43.23% | 25.51% | - |
Shares Outstanding (Basic) | 373 | 374 | 363 | 320 | 324 |
Shares Outstanding (Diluted) | 373 | 374 | 363 | 320 | 324 |
Shares Change (YoY) | -0.42% | 3.06% | 13.55% | -1.39% | 1.20% |
EPS (Basic) | -0.64 | -0.33 | 0.07 | 0.14 | 0.11 |
EPS (Diluted) | -0.64 | -0.33 | 0.07 | 0.14 | 0.11 |
EPS Growth | - | - | -50.00% | 27.27% | - |
Free Cash Flow | -49.22 | -102.43 | -178.3 | -32.97 | -52.66 |
Free Cash Flow Per Share | -0.13 | -0.27 | -0.49 | -0.10 | -0.16 |
Dividend Per Share | - | - | 0.021 | 0.037 | - |
Dividend Growth | - | - | -43.24% | - | - |
Gross Margin | 42.16% | 47.79% | 55.33% | 57.50% | 63.07% |
Operating Margin | -6.91% | -11.93% | 3.21% | 7.21% | 6.61% |
Profit Margin | -51.58% | -25.51% | 3.94% | 8.14% | 5.66% |
Free Cash Flow Margin | -10.64% | -21.17% | -27.64% | -6.00% | -8.36% |
EBITDA | 32.37 | 6.18 | 85.2 | 97.97 | 97.09 |
EBITDA Margin | 7.00% | 1.28% | 13.21% | 17.83% | 15.42% |
D&A For EBITDA | 64.33 | 63.91 | 64.49 | 58.35 | 55.49 |
EBIT | -31.96 | -57.73 | 20.71 | 39.62 | 41.6 |
EBIT Margin | -6.91% | -11.93% | 3.21% | 7.21% | 6.61% |
Effective Tax Rate | - | - | 24.11% | 17.14% | 27.05% |
Revenue as Reported | 462.78 | 483.96 | 644.97 | 549.54 | 629.76 |
Advertising Expenses | 3.34 | 6.9 | 1.86 | 2.62 | 4.47 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.